Hospital mulls research fund review

The administration of Glostrup Hospital is prepared to launch an investigation into whether its control procedures are adequate after it was revealed that a second doctor there had misused research funds for private expenses.

Dr Michael Laub is accused of spending 30,000 kroner in research funding to repay personal debts.

The news comes after it was revealed earlier this year that another of the suburban Copenhagen hospital’s doctors had syphoned off six million kroner in research funding for his own use. 

Jyllands-Posten

SEE RELATED: Transparency: better corruption legislation needed

This story was included in The Copenhagen Post's Morning Briefing for Thursday, September 19. If you would like to receive stories like these delivered to your inbox by 8am each weekday, sign up for the Morning Briefing or one of our other newsletters today. 





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.